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ABSTRACT 
 
Background and Aims: De novo malignancies after liver transplantation represent one of 
the leading causes of death in the long-term. It remains unclear if liver transplant recipients 
have an increased risk of colorectal cancer and if this negatively impacts on survival, 
particularly in those patients affected by primary sclerosing cholangitis and ulcerative colitis. 
Methods: In this national multicentre cohort retrospective study, the incidence of colorectal 
cancer in 8115 evaluable adult patients undergoing a liver transplantation between January 1
st
 
1990 and December 31
st
 2010 was compared to the incidence in the general population 
through standardised incidence ratios. 
Results: 52 (0.6%) cases of colorectal cancer were identified at a median of 5.6 years post 
liver transplantation, predominantly grade 2 (76.9%) and stage T3 (50%) at diagnosis. The 
incidence rate of colorectal cancer in the whole liver transplant population was similar to the 
general UK population (SIR 0.92), but significantly higher (SIR 7.0) in the group of patients 
affected by primary sclerosing cholangitis/ulcerative colitis. One, five and ten-year survival 
rates from colorectal cancer diagnosis were 71%, 48% and 31% respectively and the majority 
of colorectal cancer patients died of cancer-specific causes. 
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Conclusions: Liver transplantation alone is not associated with an increased risk of 
colorectal cancer development. The primary sclerosing cholangitis/ulcerative colitis liver 
transplant population showed a significantly higher risk of colorectal cancer development 
than the general population, with a high proportion of advanced stage at diagnosis and a 
reduced patient survival. 
 
 
Keywords: liver transplantation, colorectal cancer, primary sclerosing cholangitis, ulcerative 
colitis 
KEY POINTS 
1- National multicentre study on a large sample of patients transplanted over two decades 
2- This study has demonstrated significantly higher risk of colorectal cancer in the primary 
sclerosing cholangitis/ulcerative colitis group of transplanted patients but not in unselected 
liver transplant recipients when compared to the general population 
3- Low patient survival from colorectal cancer diagnosis (less than 50% at 5 years and 31% 
at 10 years), with over 20% of patients diagnosed with colorectal cancer dying from cancer-
specific causes 
 
INTRODUCTION 
 
 Liver transplant (LT) recipients have a higher risk of developing malignancies, 
particularly skin cancers and lymphoproliferative tumours
1, 2
. The risk of developing solid 
tumours is less well documented. Retrospective studies have demonstrated conflicting results 
regarding the risk of colorectal cancer (CRC) development and post-LT survival
1, 3-10
. 
According to the European Liver Transplant Register, primary sclerosing cholangitis (PSC) is 
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the primary indication for LT in approximately 5% of all adult recipients
11
 and is associated 
with inflammatory bowel disease (IBD) in up to 70% of patients
12
. In comparison to the 
general population, patients with PSC-IBD have a 10-fold increased risk of CRC, while 
patients with PSC alone have a 5-fold increased risk of CRC
12-15
. Moreover, CRC in this 
group of patients appears to develop at a younger age and is diagnosed at a more advanced 
stage compared with the general population, is predominantly localised in the ascending 
colon and represents one of the leading causes of death
12, 14
. 
A recent meta-analysis on 29 selected studies (18,875 patients: 1,732 with PSC, 111 
CRC cases), which aimed to analyse the risk of CRC in all post-LT patients indicated that the 
pooled relative risk (RR) of CRC was 2.59 in all LT recipients (7 studies were included for 
this analysis) and 1.8 in the non-PSC LT population (calculated on the results of 10 
studies)
16
. A subsequent report on 18 studies (69 cases of CRC observed in 1987 PSC 
patients and 66 of them in the 1017 PSC-IBD patients, with a mean/median post-LT follow 
up ranging from 3 to 11 years) aiming to analyse the incidence of CRC in PSC and PSC-IBD 
LT recipients, showed a high incidence rate (IR) in both groups (IR 5.8 and 13.5 cases per 
1000 person-years respectively)
17
.  
 In the present study, we used national data to assess the risk and outcome of CRC 
after LT. We therefore analysed: i) the incidence of post LT CRC and ii) whether cancer 
survival outcomes are comparable to the general population in LT patients with or without 
ulcerative colitis and with or without PSC by performing a retrospective analysis of 
prospectively collected national data in the UK. 
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MATERIALS AND METHODS 
 
 This is a national multicentre retrospective cohort study. Data from all adult patients 
undergoing a LT in 6 out of the 7 Liver Transplant Units of the United Kingdom between 
January 1
st
 1990 and December 31
st
 2010 were analysed. National ethical approval, National 
Health Service Blood and Transplant (NHSBT) approval and National Information 
Governance Board approval were obtained to perform this study. Prospectively collected 
liver transplant data was obtained from NHSBT. Retrospective data was obtained from 
electronic patient records, patient notes and hospital databases. The Yorkshire Cancer 
Registry, which is the lead UK registry for colorectal cancer, cross matched the datasets 
against the cancer registry database and provided a list of liver transplant patients with a 
diagnosis of CRC as well as the survival data on all colorectal cancer patients within the 
specified dates. Patients were followed from the first recorded liver transplant until death or 
31st December 2012. Those with evidence of colectomy prior or during first transplant were 
excluded from the analysis. 
 
 
Statistical analysis 
 
 The following populations were considered: (i) all transplanted individuals, (ii) those 
without either ulcerative colitis (UC) or PSC (iii), those with either UC or PSC and (iv) those 
with UC only. The incidence of CRC in these populations compared to that in the general 
population was assessed through Standardised incidence ratios (SIR). Age- and sex-adjusted 
estimates of the expected number of cases in each population were derived based on the rate 
of CRC in the UK general population in 2000. SIRs were calculated, for each population, as 
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the ratio of the observed/expected number of cases. People with unknown UC status were 
included in the group without UC/PSC for all analyses. Kaplan-Meier analyses estimated the 
probability of survival after CRC diagnosis for deaths from all causes. When considering 
only CRC-related causes of mortality, the cumulative incidence of death from CRC was 
estimated, treating all other causes of death as competing risks. 
 
RESULTS 
 
 8178 patients underwent a liver transplant between 1990 and 2010 in one of 6 UK 
transplant centres. 63 patients (0.8%) with a colectomy prior to or at the time of transplant 
were excluded as they were not considered to be at risk of developing CRC, leaving 8115 for 
the analysis. Median survival (95% CI) following first transplant was 15.6 (15.0-16.4) years 
and 5 and 10-year post-LT patient survival probabilities were 72% and 62% respectively. 
 52 (0.6%) patients were diagnosed with CRC at a median of 5.6 years after LT. 
Characteristics of the whole LT cohort and patients diagnosed with CRC are shown in Table 
1 and Table 2. 677 (8.3%) patients had either UC or PSC. Amongst individuals with CRC, 27 
(51.9%) had either PSC or UC. The tumour localisation was equally distributed in the 
proximal and distal colon. The tumours were moderately differentiated (grade 2) in 76.9% of 
cases and were predominantly T3 tumours (50% of cases in the whole LT population, 47.6% 
in the PSC/UC group and 66.7% in patients without PSC/UC, Table 2). 
 
CRC incidence in LT population compared to the general population 
 
Whole LT population: 
 There were a total of 63,609 person years at risk with a median (IQR) follow up time 
of 6.7 (2.9-12.2) years. This gave a crude incidence rate (95% CI) of 8.2 (6.0-10.4) cases of 
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CRC per 10,000 person years of follow up. The SIR of CRC in the liver transplant population 
compared to the general UK population was 0.92 (95% CI 0.69-1.20). The probability of 
developing a CRC after LT increases linearly over time after transplantation and is shown in 
Supplementary Figure 1. 
 
LT population with/without UC and PSC: 
 Among 7,438 patients without either UC or PSC, there were 25 (0.3%) diagnosed 
cases of CRC over a total of 58,516 person-years of follow-up, giving an incidence rate (95% 
CI) of 4.3 (2.6-6.0) per 10,000 years. The SIR (95% CI) in this group compared with the UK 
population was 0.46 (0.30-0.67). 
 Among 677 patients with either UC or PSC, there were 27 (4.0%) diagnosed cases of 
CRC over a total of 5094 person-years of follow-up, giving an incidence rate (95% CI) of 
53.0 (33.0-73.0) per 10,000 years. The rate of CRC among those with UC or PSC was 
therefore 12.3 (95% CI= 7.20-21.4) times the rate in those without UC or PSC (p<0.001). 
When compared with the UK population, the rate of CRC was 7 times higher in those with 
UC or PSC (SIR, (95% CI)= 7.00, (4.71-10.04)). 
 Among 354 patients with UC, there were 23 diagnoses of CRC in 2908 person-years 
of follow-up, giving an incidence of 79.1 (46.8-111.4) cases per 10000 person-years. When 
compared with the rate of CRC in the UK population, the SIR was 10.90 (95% CI=(7.08-
16.10)). The probability of developing a CRC after LT in patients with UC appears to be 
increasing linearly and is shown in Supplementary Figure 2. 
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Patient survival from CRC diagnosis 
 
Whole LT population (n=8,115) 
 Thirty-one (59.6%) patients with CRC died. Median (95% CI) survival from cancer 
diagnosis was 4.7 (2.1-8.0) years. One, five and ten-year survival rates from CRC diagnosis 
were 71%, 48% and 31% respectively (Figure 1A). The probability of death due to CRC at 1, 
5 and 10 years was 17.4%, 17.4% and 23.8% (Figure 1B). 
 
Population with UC or PSC (n=677) 
 There were 27 patients diagnosed with CRC who also had either UC or PSC. Of these, 
13 (48.2%) died during follow up. Median survival time was 8.0 years. One, five and ten-
year survival rates from CRC diagnosis were 81%, 59% and 47% respectively (Figure 2).  
 
Population without UC or PSC (n=7,438) 
 There were 25 patients with CRC that did not have either UC or PSC. Of these, 18 
(72%) died during follow up. Median survival time was 3.1 (0.7-6.4) years. One and five year 
survival rates from CRC diagnosis were 60%, 37% respectively (Figure 3A). The probability 
of death due to CRC at 1, 5 and 10 years was 32%, 32% and 46.6% respectively (Figure 3B). 
 
Population with UC (n=354) 
 There were 23 patients in this population with CRC. Of these, 11 (47.8%) died during 
follow up. Median survival time was 8.0 years (CI couldn’t be estimated). One, five and ten-
year survival rates from CRC diagnosis were 82%, 61% and 46% respectively (Figure 4). 
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DISCUSSION 
 
 Our study has demonstrated significantly increased risk of CRC in the PSC/UC group 
of transplanted patients (SIR 7.0) but not in the whole LT group (SIR 0.92), when compared 
with the general population. It has further shown that probably tumours are frequently 
diagnosed at an advanced stage, despite increased awareness and vigilance. 
De novo malignancies after LT adversely affect patients’ outcome, representing the 
second most common cause of death in transplant recipients (and the first from non-hepatic 
causes), accounting for over the 20% of deaths especially in the long-term after transplant
18-
21
. While the increased risk of tumour development after transplant in comparison with the 
general population has been extensively documented for malignancies such as post-transplant 
lymphoproliferative diseases or skin cancer
22-25
, analysis aimed to investigate the incidence 
of post-LT colorectal cancer have shown conflicting results
1-10, 26
. Engels et al
27
, in a large 
cohort study analysing data from the US Scientific Registry of Transplant Recipients from 
1987 to 2008, observed an overall cancer risk significantly higher than the general population 
(SIR 2.10). The CRC SIR was 1.24 (CI 1.15-1.34), but this rate referred to a mixed 
population of liver, kidney, pancreas, heart and lung transplant recipients, with liver 
transplants representing only the 22.6% of the total. The discrepancy in the results from our 
study might be due to the relatively lower immunosuppression doses required by liver 
transplant recipients 
Recently, Sint Nicolaas et al
16
 and Singh et al
17
 conducted meta-analyses in order to 
estimate RR and incidence rate (IR) of CRC in LT recipients, specifically in the PSC and 
non-PSC groups. They concluded that the whole LT population (RR 2.59, 95% CI 2.12-5.24), 
the non-PSC group (RR 1.8, 95% CI 1.1-2.9), and the PSC-IBD group (IR 13.5 cases per 
1000 person-years) all carry an increased risk of CRC development, although no transplant-
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related risk factors had been identified. However, both these analyses had several limitations, 
such as evidence of publication bias (statistically significant Egger’s test with p=0.0716 and 
p=0.01
17
), inclusion of only a small proportion of high-quality studies (6/29 in Sint Nicolaas 
and 7/18 in Singh’s reviews respectively), considerable heterogeneity (moderate in Singh’s 
review, with p=0.03 (Cochran’s Q), I2=41%) and the inclusion of several studies variably 
accounting for the competing risk of post-LT early mortality and colectomy, that could 
significantly underestimate the CRC IR.
 
 
 To the best of our knowledge, we describe in the present study the results from both 
the largest European LT and LT-PSC/UC cohort published in the literature (8115 and 677 
patients respectively). Although solid organ malignancies have been reported to occur in 
about 11% of LT recipients
21
, and several studies
1, 8, 28-30
 report a high incidence of post-LT 
CRC, we observed no increased incidence in the whole LT population, with a crude 
incidence rate (95% CI) of 8.2 (6.0-10.4) cases of CRC per 10,000 person years of follow up 
and  SIR 0.92. This finding is in contrast with what has been observed in the meta-analysis by 
Sint Nicolaas and colleagues
16
, where the CRC IR in the overall post-LT patients was 11.9 
cases per 10,000 person years (data calculated on 9620 patients from 15 studies, with a 
statistically significant Egger’s test (p=0.07), indicating a possible publication bias). In order 
to calculate the RR in overall post-LT patients, the authors compared the results of 7 studies 
(6200 patients) with data from the United States NCI SEER database, which showed a lower 
CRC IR (7.8 cases per 10,000 person years of follow up) when compared with our control 
general UK population, and results in a RR of 2.59 in overall post-LT patients. 
 Patients with PSC/UC have been reported to have an increased risk of CRC 
development
12-15
, potentially with a greater risk after LT due to a possible contribution of 
other factors such as the immunosuppressive therapy or a more aggressive course of the IBD 
after transplant
31-34
. 
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 Our analysis identified the PSC/UC group as at significantly increased risk for CRC 
development after LT either when compared to the general population (SIR 7) or the non-
PSC/UC LT recipients (SIR 12.3). Moreover, patients with UC showed a risk of CRC 
development over 10 times higher than the general population (SIR 10.9). These results are 
similar to those of a recent study on the whole US transplant population
35
 where PSC and 
IBD LT recipients showed an increased CRC risk.  
 We estimated a SIR of 7, which is higher than the SIR of 5 reported by Boonstra and 
colleagues
12
 in a PSC population not undergoing LT. Comparing these results it is important 
to consider that these populations are not matched for the time from PSC diagnosis. The CRC 
risk distribution in PSC/IBD patients increases with time
2
 as the duration and the extent of 
the disease represent the predominant risk factors for tumour development
36, 37
. Therefore the 
greater SIR after LT could just reflect a longer duration of the underlying disease in this 
population. Our results have shown a linear increase of probability of developing a CRC after 
LT in the whole LT population and in patients with UC (Supplementary Figures 1 and 2). 
The LT recipients are also burdened by the possible role of the drug-induced 
immunosuppression in the carcinogenesis
28, 35, 38
. The mechanisms involved in CRC 
development in PSC patients are still unclear. Multiple factors, such as alteration in bile acids 
pool, increased concentration of secondary bile acids, microbiome dysbiosis, Farnesoid X 
Receptor downregulation and colonic mucosal inflammation, may play a central role in 
carcinogenesis
14, 39
. 
 Most previous series
12, 14, 40
 demonstrate a predominance of right-sided tumour 
distribution (up to 76%) unlike our series which shows an equal distribution across all 
locations with <50% of tumours in the right colon, but unfortunately data on tumour location 
were missing in about 34% of patients. 
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 When compared with the general UK population
41
, we report CRC being diagnosed at 
a more advanced stage with 65% of tumours being T3-T4. We also found that patient 
survival from CRC diagnosis was less than 50% at 5 years and 31% at 10 years. Over 20% of 
patients diagnosed with CRC died from cancer-specific causes during the follow-up. Our 
results demonstrated superior patient survival from CRC diagnosis in the PSC/UC population 
than in the whole LT population and in patients without PSC/UC (Figures 1A, 2 and 3A).  
 Limitations of the present study include the retrospective nature of data collection that 
were incomplete for some parameters, such as LT indication and CRC characteristics. The 
heterogeneity of the different centres’ policies regarding post-LT colonoscopy did not allow 
evaluation of whether a screening protocol might be able to improve earlier diagnosis. 
However, liver transplant candidates and recipients are likely to have undergone colonoscopy 
(and possibly polypectomy) more frequently than the general population as part of the pre-LT 
evaluation or post-LT follow up, and this might have resulted in a reduction of the risk of 
CRC development. This further strengthens the finding of increased CRC risk in patients 
transplanted for PSC. In the UK, there is a nationwide screening for CRC development with 
faecal blood assays every 2 years offered to all men and women aged 60 to 74. Moreover, 
due to the small number of patients developing a post LT CRC, it was not possible to perform 
a uni- and multivariate analysis to identify independent risk factors for CRC development.  
 In conclusion, our results suggest that LT in unselected patients is not associated with 
an increased risk of CRC development. The PSC/UC LT population showed a significantly 
increased risk of CRC development (7 times higher than the general population). Considering 
the patient survival and the possible high proportion of advanced CRC stage at diagnosis, a 
long-term post LT screening program would be advisable in patients with PSC/UC and an 
intact colon. In this scenario, prophylactic colectomy could play a role, since it has been 
demonstrated that PSC patients who had a pre-LT colectomy or don’t suffer from UC carry a 
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significantly lower risk of recurrent PSC when compared to patients with UC and no 
colectomy, which is strongly associated to an increased rate of graft failure and patient 
death
42
. 
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Table 1: Whole LT Population Patient Characteristics 
 Whole LT population 
  
Years of follow-up, median (IQR) 
Age at transplant, median (IQR) 
6.8 (2.9-12.3) 
51 (41-59) 
Male, n (%) 4327 (53.3) 
Main indication, n (%) 
PSC 
PBC 
alcoholic liver disease 
HCV-related cirrhosis 
HBV-related cirrhosis 
autoimmune hepatitis 
cryptogenic cirrhosis 
alpha-1 antitrypsin deficit 
urgent/fulminant liver failure 
HCC 
haemocromatosis 
metabolic 
polycystic liver disease 
all other indications/unknown 
 
605 (7.5) 
981 (12.1) 
1414 (17.4) 
980 (12.1) 
325 (4) 
296 (3.7) 
395 (4.9) 
79 (1) 
962 (11.9) 
294 (3.6) 
62 (0.8) 
83 (1) 
53 (0.7) 
1587 (19.6) 
Total, n 8115 
LT= liver transplant, IQR= interquartile range, PSC= primary sclerosing cholangitis, PBC= 
primary biliary cirrhosis, HCV= hepatitis C virus, HBV= hepatitis B virus, HCC= 
hepatocellular carcinoma 
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Table 2: CRC Patient Characteristics 
 CRC population 
  
Age at transplant, median (IQR) 56 (48-61) 
Male, n (%) 35 (67.3) 
Transplant for PSC, n (%) 24 (46.2) 
Presence of UC, n (%) 23 (44.2) 
Time to diagnosis (years), median (IQR) 
Tumour location, n (%)* 
caecum/ascending/hepatic flexure 
transverse 
splenic flexure/descending/sigmoid 
rectum 
Type of surgery, n (%)** 
right/extended right hemicolectomy 
left/sigmoid colectomy 
subtotal colectomy 
panproctocolectomy 
anterior resection 
Tumour grade, n (%)
§
 
1 
2 
3 
Tumour Stage, n(%)
§§
 
Tis 
T1 
T2 
T3 
T4 
Nx 
N0 
N1 
5.6 (3.8-8.8) 
 
13 (38.2) 
4 (11.8) 
9 (26.5) 
8 (23.5) 
 
14 (33.3) 
4 (9.5) 
2 (4.8) 
14 (33.3) 
9 (21.4) 
 
2 (7.7) 
20 (76.9) 
4 (15.4) 
 
2 (6.1) 
2 (6.1) 
6 (18.2) 
18 (50) 
5 (15.2) 
1 (3) 
20 (60.6) 
9 (27.3) 
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N2 
M0 
M1 
Total, n 
3 (9.1) 
24 (72.7) 
9 (27.3) 
52 
CRC= colorectal cancer, IQR= quartile range, PSC= primary sclerosing cholangitis, UC= 
ulcerative colitis, *n=34, **n=42, §=26, §§=33 
 
 
 
Figure 1: (A) Kaplan-Meier plot of patient survival from diagnosis of CRC in those with 
liver transplant. (B) Cumulative Incidence for death due to colorectal cancer amongst LT 
population with CRC. CRC= colorectal cancer, LT= liver transplant. 
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Figure 2: Kaplan Meier plot of survival from CRC diagnosis in population with UC and 
PSC. CRC= colorectal cancer, PSC= primary sclerosing cholangitis, UC= ulcerative colitis. 
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Figure 3: (A) Kaplan Meier plot of survival from CRC diagnosis in LT population without 
PSC or UC. (B) Probability of CRC death amongst CRC patients without UC or PSC. CRC= 
colorectal cancer, LT= liver transplant, PSC= primary sclerosing cholangitis, UC= ulcerative 
colitis. 
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Figure 4: Kaplan Meier plot of survival from CRC diagnosis in LT population with UC. 
CRC= colorectal cancer, LT= liver transplant, UC= ulcerative colitis. 
 
 
 
 
 
